Phase 3 trials have made major contributions to advances in prostate cancer (PCa). However, funding limitations and excess bureaucracy are now making it difficult to conduct trials
Purpose Evolving treatments, disease phenotypes, and biology, together with a changing drug developm...
Background: In 2005, the US Department of Defense, through the US Army Medical Research and Materiel...
To describe the results of 3 rounds of diagnostic testing and linkage to the Dutch Cancer Registry f...
CONTEXT: Phase 3 trials have made major contributions to advances in prostate cancer (PCa). However...
CONTEXT: Phase 3 trials have made major contributions to advances in prostate cancer (PCa). However,...
AbstractBackground It is not easy to overview pending phase 3 trials on prostate cancer (PCa), and a...
The Prostate Cancer Programme of the European School of Oncology developed the concept of specialise...
nerp, plasia (BPH), and PCa—and their relationship to prostate- public scrutiny. Most of our big hos...
Prostate cancer (PCa) is one of the first three causes of cancer mortality in Europe. Screening in a...
Two large-scale randomized screening trials, the Prostate, Lung, Colorectal and Ovary (PLCO) cancer ...
The Prostate Cancer Programme of the European School of Oncology developed the concept of specialise...
BACKGROUND: High-quality management of prostate cancer is needed in the fields of clinics, research,...
Prostate cancer (PCa)is one of the first three causes of cancer mortality in Europe. Screening in as...
Objectives: This report summarises major new findings in the field of prostate cancer (PCa) presente...
The Prostate Cancer Programme of the European School of Oncology developed the concept of specialise...
Purpose Evolving treatments, disease phenotypes, and biology, together with a changing drug developm...
Background: In 2005, the US Department of Defense, through the US Army Medical Research and Materiel...
To describe the results of 3 rounds of diagnostic testing and linkage to the Dutch Cancer Registry f...
CONTEXT: Phase 3 trials have made major contributions to advances in prostate cancer (PCa). However...
CONTEXT: Phase 3 trials have made major contributions to advances in prostate cancer (PCa). However,...
AbstractBackground It is not easy to overview pending phase 3 trials on prostate cancer (PCa), and a...
The Prostate Cancer Programme of the European School of Oncology developed the concept of specialise...
nerp, plasia (BPH), and PCa—and their relationship to prostate- public scrutiny. Most of our big hos...
Prostate cancer (PCa) is one of the first three causes of cancer mortality in Europe. Screening in a...
Two large-scale randomized screening trials, the Prostate, Lung, Colorectal and Ovary (PLCO) cancer ...
The Prostate Cancer Programme of the European School of Oncology developed the concept of specialise...
BACKGROUND: High-quality management of prostate cancer is needed in the fields of clinics, research,...
Prostate cancer (PCa)is one of the first three causes of cancer mortality in Europe. Screening in as...
Objectives: This report summarises major new findings in the field of prostate cancer (PCa) presente...
The Prostate Cancer Programme of the European School of Oncology developed the concept of specialise...
Purpose Evolving treatments, disease phenotypes, and biology, together with a changing drug developm...
Background: In 2005, the US Department of Defense, through the US Army Medical Research and Materiel...
To describe the results of 3 rounds of diagnostic testing and linkage to the Dutch Cancer Registry f...